Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis

Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Key Stats

• Today's Range: $7.40 to $7.53
• 50-Day Range: $7.12 to $8.56
• 52-Week Range: $4.79 to $8.65
• Volume: 753,682 shs
• Average Volume: 1.18 million shs
• Market Capitalization: $29.59 billion
• P/E Ratio: N/A
• Dividend Yield: 0.27%
• Price Target: N/A
• Consensus Rating: Buy

BAYRY Stock Analysis - Frequently Asked Questions

How have BAYRY shares performed this year?

Bayer Aktiengesellschaft's stock was trading at $4.88 at the beginning of the year. Since then, BAYRY stock has increased by 54.3% and is now trading at $7.53.

How were Bayer Aktiengesellschaft's earnings last quarter?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) announced its quarterly earnings data on Wednesday, August, 6th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.25 by $0.10. The company earned $12.42 billion during the quarter, compared to analysts' expectations of $10.79 billion. Bayer Aktiengesellschaft had a positive trailing twelve-month return on equity of 15.48% and a negative net margin of 7.61%.

Does Bayer Aktiengesellschaft have any subsidiaries?

The following companies are subsidiaries of Bayer Aktiengesellschaft: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and others.

How do I buy shares of Bayer Aktiengesellschaft?

Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 5/12 Dividend: 4/29/2025
• Record date for 5/12 Dividend: 4/30/2025
• Dividend Payable: 5/12/2025
• Last Earnings: 8/06/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BAYRY
• CIK: 1144145
• Web: www.bayer.com
• Phone: 49214301
• Fax: 49-21-4306-6328
• Employees: 92,815
• Year Founded: 1863

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.75
• P/E Growth: N/A
• Net Income: -$2.76 billion
• Net Margins: -7.61%
• Pretax Margin: -6.83%
• Return on Equity: 15.48%
• Return on Assets: 4.51%

Debt

• Debt-to-Equity Ratio: 1.07
• Current Ratio: 1.25
• Quick Ratio: 0.79

Sales & Book Value

• Annual Sales: $50.44 billion
• Price / Sales: 0.59
• Cash Flow: $3.86 per share
• Price / Cash Flow: 1.95
• Book Value: $8.82 per share
• Price / Book: 0.85

Miscellaneous

• Outstanding Shares: 3,929,700,000
• Free Float: N/A
• Market Cap: $29.59 billion
• Optionable: Not Optionable
• Beta: 0.91